AR032391A1 - Metodo de elaboracion de vacuna combinada y producto resultante - Google Patents

Metodo de elaboracion de vacuna combinada y producto resultante

Info

Publication number
AR032391A1
AR032391A1 ARP020100060A ARP020100060A AR032391A1 AR 032391 A1 AR032391 A1 AR 032391A1 AR P020100060 A ARP020100060 A AR P020100060A AR P020100060 A ARP020100060 A AR P020100060A AR 032391 A1 AR032391 A1 AR 032391A1
Authority
AR
Argentina
Prior art keywords
combined vaccine
diphtheria
hepatitis
pertussis
tetanus
Prior art date
Application number
ARP020100060A
Other languages
English (en)
Inventor
Youn-Kyeong Lee
Wan-Kyu Kim
Hee-Ku Lee
Won-Kyum Kim
Kyu Wan Kim
Hyi-Jeong Ji
Original Assignee
Lg Chem Investment Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=19704448&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR032391(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lg Chem Investment Ltd filed Critical Lg Chem Investment Ltd
Publication of AR032391A1 publication Critical patent/AR032391A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
    • A61K39/0017—Combination vaccines based on whole cell diphtheria-tetanus-pertussis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
    • A61K39/0018—Combination vaccines based on acellular diphtheria-tetanus-pertussis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Se refiere a un método para elaborar una vacuna combinada capaz de prevenir concurrentemente multiples enfermedades que deberían prevenirse en un infante, tales como difteria, tétanos, pertussis y hepatitis B. El método para elaborar una vacuna combinada incluye los pasos de adsorber independientemente cada antígeno protector a un adsorbente de gel de hidroxido de aluminio con respecto a diferentes enfermedades tales como difteria, tétanos pertussis y hepatitis B, las que deberían prevenirse en los ninos y combinar cada antígeno protector adsorbido al adsorbente luego de la adsorcion. Así es posible prevenir concurrentemente multiples enfermedades tales como difteria, tétanos, pertussis y hepatitis B las que deben prevenirse en el infante utilizando una vacuna combinada.
ARP020100060A 2001-01-10 2002-01-09 Metodo de elaboracion de vacuna combinada y producto resultante AR032391A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR10-2001-0001290A KR100401423B1 (ko) 2001-01-10 2001-01-10 혼합 백신의 제조 방법

Publications (1)

Publication Number Publication Date
AR032391A1 true AR032391A1 (es) 2003-11-05

Family

ID=19704448

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020100060A AR032391A1 (es) 2001-01-10 2002-01-09 Metodo de elaboracion de vacuna combinada y producto resultante

Country Status (21)

Country Link
US (2) US20040048336A1 (es)
EP (1) EP1349572B1 (es)
JP (1) JP3977257B2 (es)
KR (1) KR100401423B1 (es)
CN (1) CN1228086C (es)
AR (1) AR032391A1 (es)
AT (1) ATE373485T1 (es)
AU (1) AU2002219693B2 (es)
BR (1) BR0206391A (es)
CA (1) CA2434421C (es)
DE (1) DE60222529T2 (es)
ES (1) ES2291466T3 (es)
IL (1) IL156791A0 (es)
MX (1) MXPA03006154A (es)
MY (1) MY143688A (es)
PE (1) PE20020758A1 (es)
PL (1) PL211005B1 (es)
RU (1) RU2264226C2 (es)
UY (1) UY27118A1 (es)
WO (1) WO2002055105A1 (es)
ZA (1) ZA200305072B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69319728T2 (de) 1992-05-23 1999-02-04 Smithkline Beecham Biolog Kombinierte Impfstoffe, die Hepatitis B oberfläche Antigen und andere Antigenen enthalten
GB0505996D0 (en) 2005-03-23 2005-04-27 Glaxosmithkline Biolog Sa Fermentation process
GB0522765D0 (en) * 2005-11-08 2005-12-14 Chiron Srl Combination vaccine manufacture
CA2654014A1 (en) * 2006-05-31 2007-12-06 Silvio Buzzi Pharmaceutical use of protein molecules immunologically correlated to diphtheria toxin
GB0616306D0 (en) * 2006-08-16 2006-09-27 Novartis Ag Vaccines
PT2097102E (pt) * 2006-09-07 2012-08-03 Glaxosmithkline Biolog Sa Vacina de combinação tendo quantidades reduzidas de antigénio de poliovírus
GB0822633D0 (en) * 2008-12-11 2009-01-21 Novartis Ag Formulation
IT1398927B1 (it) 2009-06-25 2013-03-28 Consorzio Interuniversitario Per Lo Sviluppo Dei Sistemi A Grande Interfase Csgi Espressione batterica di un gene artificiale per la produzione di crm197 e derivati.
GB0917647D0 (en) 2009-10-08 2009-11-25 Glaxosmithkline Biolog Sa Expression system
CN102363041A (zh) * 2011-11-17 2012-02-29 成都欧林生物科技股份有限公司 不含防腐剂疫苗的制作工艺
KR101518473B1 (ko) 2013-03-14 2015-05-07 (주)바이오인디스트 애완견의 바이러스성 전염병 예방 및 치료용 복합 난황 항체 조성물 및 그 제조방법
AR102548A1 (es) 2014-11-07 2017-03-08 Takeda Vaccines Inc Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y uso
AR102547A1 (es) * 2014-11-07 2017-03-08 Takeda Vaccines Inc Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y su uso
WO2022114921A1 (ko) * 2020-11-30 2022-06-02 주식회사 엘지화학 알루미늄 부형제를 이용하여 다가 혼합백신 내 백일해 균 유래 엔도톡신 제거 방법

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU188847B (en) * 1983-02-22 1986-05-28 Human Oltoanyagtermeloe Es Kutato Intezet,Hu Process for producing liophylized combined vaccines
CA1213234A (en) * 1983-03-30 1986-10-28 Akihiro Ginnaga Method for the production of ha fraction containing protective antigens of bordetella pertussis and pertussis vaccine
US4649192A (en) * 1985-05-30 1987-03-10 Smith Kline-Rit Method for the isolation and purification of hepatitis B surface antigen using polysorbate
EP0251575B2 (en) * 1986-06-17 2002-11-13 Chiron Corporation Hepatitis delta diagnostics and vaccines, their preparation and use
JPH085804B2 (ja) * 1988-04-28 1996-01-24 財団法人化学及血清療法研究所 Ａ型及びｂ型肝炎混合アジュバントワクチン
EP0484621A3 (en) * 1990-07-11 1992-08-26 American Cyanamid Company Efficacious vaccines against bordetella pertussis comprising a combination of individually purified pertussis antigens
DE69319728T2 (de) * 1992-05-23 1999-02-04 Smithkline Beecham Biolog Kombinierte Impfstoffe, die Hepatitis B oberfläche Antigen und andere Antigenen enthalten
US6372225B1 (en) * 1996-03-23 2002-04-16 The Research Foundation Of Microbial Diseases Of Osaka University Tetanus toxin functional fragment antigen and tetanus vaccine
GB9611501D0 (en) * 1996-06-03 1996-08-07 Smithkline Beecham Biolog Vaccine compositions
CA2259415A1 (en) * 1996-07-02 1998-01-08 Connaught Laboratories Limited Multivalent dtp-polio vaccines
GB9623233D0 (en) * 1996-11-07 1997-01-08 Smithkline Beecham Biolog Vaccine composition
BR9714980A (pt) * 1997-09-15 2001-11-06 Pasteur Merieux Msd Vacinas multivalentes
GB9806456D0 (en) * 1998-03-25 1998-05-27 Smithkline Beecham Biolog Vaccine composition

Also Published As

Publication number Publication date
UY27118A1 (es) 2002-08-30
ZA200305072B (en) 2003-09-17
CA2434421A1 (en) 2002-07-18
RU2264226C2 (ru) 2005-11-20
AU2002219693B2 (en) 2006-03-16
DE60222529T2 (de) 2008-06-19
US20040048336A1 (en) 2004-03-11
DE60222529D1 (de) 2007-10-31
MXPA03006154A (es) 2003-09-16
ATE373485T1 (de) 2007-10-15
PL369433A1 (en) 2005-04-18
JP2004517866A (ja) 2004-06-17
EP1349572A1 (en) 2003-10-08
PE20020758A1 (es) 2002-08-29
BR0206391A (pt) 2004-07-27
CA2434421C (en) 2012-02-21
EP1349572B1 (en) 2007-09-19
EP1349572A4 (en) 2004-09-15
MY143688A (en) 2011-06-30
KR20020060298A (ko) 2002-07-18
PL211005B1 (pl) 2012-03-30
CN1484531A (zh) 2004-03-24
RU2003124660A (ru) 2005-01-10
CN1228086C (zh) 2005-11-23
ES2291466T3 (es) 2008-03-01
US20090181050A1 (en) 2009-07-16
JP3977257B2 (ja) 2007-09-19
KR100401423B1 (ko) 2003-10-17
IL156791A0 (en) 2004-02-08
WO2002055105A1 (en) 2002-07-18

Similar Documents

Publication Publication Date Title
AR032391A1 (es) Metodo de elaboracion de vacuna combinada y producto resultante
AR073959A1 (es) Vacuna de combinacion con tos ferina acelular y metodo para su elaboracion
PL1635863T3 (pl) Kompozycje do wywoływania, wzmacniania i utrzymywania odpowiedzi immunologicznych na epitopy ograniczone do MHC klasy I do celów profilaktycznych i leczniczych
AR042236A1 (es) Panal desechable con cinturon de sujecion
AR014762A1 (es) PROCEDIMIENTO PARA REDUCIR LA INTERFERENCIA DE COMPONENTES POLISACARIDOS CAPSULARES, DE VACUNAS CONJUGADAS DE HAEMOPHILUS INFLUENZAE B (Hib) EN VACUNASDE COMBINACION, VACUNAS DE COMBINACION OBTENIDAS CON DICHO PROCEDIMIENTO DE VACUNACION CONTRA LA DIFTERIA, TETANO, PERTUSSIS Y HAEMOPHILUS INFLUENZAE
CY1118629T1 (el) Εμβολιο ιου ερπητα ζωστηρα
AR025750A1 (es) Vacunas
EA200702633A1 (ru) Вакцина против малярии
UY27720A1 (es) Aroilpiridinonas monocíclicas,
IL184273A0 (en) Methods to elicit, enhance and sustain immune responses against mhc class i-restricted epitopes, for prophylactic or therapeutic purposes
NO20015073L (no) Vaksiner
PL1928492T3 (pl) Immunologiczne zastosowania związków immunomodulujących do szczepionki i przeciwzakaźnego leczenia choroby
ATE546182T1 (de) Gerät zur unterstützung der atmung
CY1108521T1 (el) Παρασκευη αλδεσλευκινης για φαρμακευτικη χρηση
AR011509A1 (es) Composicion de vacuna que comprende antigenos de difteria, tetano y tos ferina(pertusis) acelular y su uso para la manufactura de un medicamento util como reforzador de vacuna.
DE602005027469D1 (de) Pharmazeutische zusammensetzung mit verzögerter freisetzung aus tolterodin
AR060469A1 (es) Aparato para aerosol, en particular para ninos
CO6430435A2 (es) Nuevas vacunas combinadas con células completas de pertussis y método de fabricación de las mismas
WO2003080111A3 (en) Chemotherapeutic agents as anti-cancer vaccine adjuvants and therapeutic methods thereof
AR039982A1 (es) Composicion vacunal contra las alergias, metodo para su obtencion y empleo en el tratamiento de las mismas
CU22871A1 (es) Formulaciones conteniendo partículas semejantes a virus como inmunopotenciadores por vía mucosal
TH61084A (th) วิธีการผลิตวัคซีนรวม
CU23496A1 (es) Composición vacunal contra el virus de la hepatitis c
AR023536A1 (es) Vacunas
EP1181077B8 (en) Ball game apparatus